RARE
Ultragenyx
15.30$
+2.7%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures per share in USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | 0.00 | 0.00 | 0.00 | 0.06 | 1.03 | 1.83 | 4.45 | 5.18 | 5.20 | 5.90 | 6.19 | 6.83 | |
| – | – | – | 0.00 | 0.04 | 4.63 | 0.00 | 0.02 | 0.16 | 0.10 | 0.24 | 0.41 | 0.61 | 0.85 | 1.11 | |
| – | – | – | 0.00 | -0.04 | 0.00 | 0.06 | 1.01 | 1.67 | 4.35 | 4.95 | 4.79 | 5.29 | 5.34 | 5.72 | |
| 0.20 | 0.55 | 0.96 | 1.60 | 3.12 | 4.63 | 5.46 | 5.91 | 6.32 | 6.77 | 7.33 | 10.10 | 8.82 | 7.71 | 7.61 | |
| 0.08 | 0.14 | 0.15 | 0.38 | 0.90 | 1.64 | 2.35 | 2.57 | 2.85 | 3.01 | 3.24 | 3.98 | 4.21 | 3.55 | 3.54 | |
| 0.28 | 0.69 | 1.11 | 1.97 | 4.02 | 6.27 | 7.81 | 8.47 | 9.17 | 9.78 | 10.58 | 14.07 | 13.03 | 11.26 | 11.15 | |
| -0.28 | -0.69 | -1.11 | -1.97 | -4.02 | -6.26 | -7.75 | -7.46 | -7.50 | -5.43 | -5.63 | -9.28 | -7.74 | -5.92 | -5.43 | |
| 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.55 | 0.43 | 0.62 | 0.90 | 0.70 | 0.63 | |
| -0.30 | -0.71 | -1.21 | -2.08 | -3.96 | -6.21 | -7.50 | -3.96 | -7.06 | -3.05 | -6.68 | -10.04 | -8.27 | -6.27 | -5.79 | |
| 0.01 | -0.02 | -0.10 | -0.02 | -0.06 | 0.00 | -0.38 | 0.01 | 0.06 | 0.02 | 0.02 | 0.08 | -0.02 | 0.02 | 0.04 | |
| -0.30 | -0.71 | -1.21 | -2.08 | -3.96 | -6.21 | -7.12 | -3.97 | -7.12 | -3.07 | -6.70 | -10.12 | -8.25 | -6.29 | -5.83 | |
| -0.28 | -0.69 | -1.19 | -1.95 | -3.98 | -6.18 | -7.61 | -3.57 | -6.89 | -2.30 | -6.05 | -9.16 | -7.02 | -5.18 | -4.81 |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.